Neonatal Pulmonary Hypertension: Diagnosis, Management, and Future
Received Date: Oct 05, 2025 / Published Date: Nov 03, 2025
Abstract
Neonatal pulmonary hypertension (PPHN) remains a significant cause of neonatal mortality, characterized by elevated pulmonary
arterial pressure. This review synthesizes current understanding of PPHN pathophysiology, diagnosis, and management. Key thera
peutic strategies include inhaled nitric oxide (iNO), sildenafil, and extracorporeal membrane oxygenation (ECMO) for severe cases.
Advances in molecular mechanisms and novel pharmacologic targets are being explored. Long-term neurodevelopmental outcomes
in survivors are a concern, necessitating early screening. Ventilatory strategies and emerging therapies hold promise for improving
outcomes in affected neonates.
Citation: Cohen DR (2025) Neonatal Pulmonary Hypertension: Diagnosis, Management, and Future. NNP 11: 590.
Copyright: 漏 2025 Dr. Rachel Cohen This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 230
- [From(publication date): 0-0 - Apr 07, 2026]
- Breakdown by view type
- HTML page views: 175
- PDF downloads: 55
